Although U.S. companies are reeling under the uncertain impacts of the coronavirus, Procter & Gamble's (PG) recent move to hike dividend comes as a sigh of relief for investors.
Perrigo Company plc (NYSE:PRGO) came out with its quarterly results last week, and we wanted to see how the business...
Perrigo (PRGO) reports decent first-quarter 2019 results. The addition of products following Ranir acquisition and stock piling due to COVID-19 boosts sales in the quarter.
Perrigo (PRGO) delivered earnings and revenue surprises of 4.59% and 1.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
DEEP DIVE The COVID-19 pandemic has accelerated some health-care trends while opening people’s eyes to others that now seem obvious. Analysts at investment bank Jefferies have listed stocks of companies they argue are likely winners and losers from those trends.
Dividend paying stocks like Perrigo Company plc (NYSE:PRGO) tend to be popular with investors, and for good reason...
The medical product companies have partially mitigated the impact of the pandemic driven by the massive adoption of COVID-19 related healthcare-support products and services.
Perrigo Company plc (NYSE; TASE: PRGO) today announced that President and CEO Murray S. Kessler will host a fireside chat at the RBC Capital Markets Global Healthcare Conference at 11:30 AM EDT on Wednesday, May 20, 2020. Interested parties can access the presentation webcast at http://perrigo.investorroom.com/events-webcasts.
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
PRGO earnings call for the period ending March 31, 2020.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
The Perrigo Company plc (NYSE; TASE: PRGO) Board of Directors considers the well-being of shareholders, employees and service providers at the upcoming Annual General Meeting ("AGM") a primary concern and, in this context, has been closely monitoring developments in relation to the Coronavirus (COVID-19).
Perrigo (PRGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo Co. said late Tuesday it experienced a first-quarter sales boost due to the COVID-19 pandemic. The over-the-counter drug maker said it expects adjusted operating income of $220 million to $225 million on revenue of about $1.3 billion. Analysts surveyed by FactSet expect adjusted operating income of $195 million, or earnings of 96 cents a share, on revenue of $1.26 billion. "During the first quarter, Perrigo continued to experience strong growth across all business segments, while also benefiting from a dramatic surge in demand in March related to the COVID-19 pandemic," Murray Kessler, Perrigo chief executive, said in a statement. Perrigo shares rose 3.2% after hours, following a 1% decline to close at $47.08 in the regular session.
A few favorable signals are starting to emerge on the charts of the private-label maker of pharmaceutical and wellness products.
Perrigo Company plc (NYSE; TASE: PRGO) today announced that President and CEO Murray S. Kessler will present as part of the Goldman Sachs Global Staples Forum Webcast at 8:10 AM EST on Monday, May 18, 2020. Interested parties can access the presentation webcast at http://perrigo.investorroom.com/events-webcasts.
Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its first quarter financial results on Thursday, April 30, 2020. The Company will also host a conference call beginning at 8:30 a.m. (EST).
Q1 2020 Perrigo Company PLC Earnings Call
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.225 per share, payable on June 16, 2020 to shareholders of record on May 29, 2020.